It is time to move past the idea that in the development and commercialization of cell and gene therapies ‘the process is the product.’ AmplifyBio aims to replace that saying with a new one: ‘the product is the product.‘ The addition of these capabilities to complement our in vivo preclinical work means that cell and gene therapies can now be differentiated based on safety and efficacy profiles and specific product characteristics, not development processes.
These capabilities were added through an asset acquisition of a site, platforms, and broad domain expertise from PACT Pharma. PACT is a clinical-stage company developing neoantigen-specific T cell receptor cell therapies. As a result of this deal, PACT will continue its development work, while AmplifyBio will be able to leverage established platforms and processes to offer optimization, characterization, safety, and efficacy services to preclinical clients, particularly those seeking to better understand the immunology of their advanced therapies.
With the expertise to design the right study for every model and flexibility for data-driven implementation, AmplifyBio is your partner to trust for Preclinical Contract Research Organization Services. Talk with us and discover how we can support your study and compliance requirements.